60 Degrees Pharmaceuticals Announces 2025 Annual Results [Yahoo! Finance]
60 Degrees Pharmaceuticals, Inc. (SXTP)
Company Research
Source: Yahoo! Finance
WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, reported today its financial results for the 2025 fiscal year ended December 31, 2025. Financial Highlights for the Fiscal Year Ended December 31, 2025: Net product revenues increased 65% from $607.6 thousand in 2024 to $1.0 million in 2025, driven by rising sales, price increases, and fewer returns. The Company achieved a gross profit of approximately $223.8 thousand in 2025, compared with approximately $222.8 thousand in 2024. Gross profit remained relatively stable despite inventory write-offs associated with a final batch of short-dated product entering the supply chain. This charge was a necessary, non-recurring cost incurred as part of scaling operations. Operating expenses were approximately $8.4 million in 2025, compared with approximately $10.0 million in 2024. The d
Show less
Read more
Impact Snapshot
Event Time:
SXTP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SXTP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SXTP alerts
High impacting 60 Degrees Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SXTP
News
- 60 Degrees Pharmaceuticals (SXTP) had its price target lowered by Ascendiant Capital Markets from $11.20 to $4.20. They now have a "buy" rating on the stock.MarketBeat
- 60 Degrees Pharmaceuticals (SXTP) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SXTP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> froMarketBeat
- 60 Degrees Pharmaceuticals Announces 2025 Annual ResultsGlobeNewswire
- 60 Degrees Pharmaceuticals (SXTP) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SXTP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> to MarketBeat
- 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract [Yahoo! Finance]Yahoo! Finance
SXTP
Analyst Actions
- 4/9/26 - Ascendiant Capital
SXTP
Sec Filings
- 3/30/26 - Form 10-K
- 3/20/26 - Form 8-K
- 3/13/26 - Form 424B5
- SXTP's page on the SEC website